Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Unknown 35 enrolled Yuankai Shi

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.

Timeline

Start: 2016-09
Primary completion: 2019-03
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tucidinostat	Small molecule	20 mg	Oral
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	0.4 g	Other
Background	Carboplatin	Small molecule	4 unknown	Other
Background	Etoposide	Small molecule	65 mg/m2	Other
Background	Ifosfamide	Small molecule	1200 mg/m2	Other

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Summary

Timeline

Drugs

Indications